At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 5 enrolled
Drug / intervention
PF-07304814drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO INVESTIGATE THE MASS BALANCE, METABOLISM AND EXCRETION OF [14C]-PF-07304814 IN HEALTHY PARTICIPANTS USING A 14C-MICROTRACER APPROACH
In Brief
A Phase 1 clinical trial evaluating PF-07304814 for Healthy. Completed, enrolled 5 participants across 1 site.
Detailed Summary
This open-label, single dose study in approximately 5 healthy male and female (of non childbearing potential only) participants has been designed to characterize mass balance and further the understanding of human pharmacokinetics, metabolism, and excretion of PF 07304814 administered at a dose of 500 mg \[14C\] PF-07304814 containing approximately 420 nCi \[14C\] PF-07304814 as a constant-rate, continuous IV infusion over 24 hours
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedSep 2021
Enrollment StartOct 2021
Primary CompletionDec 2021
TodayJul 2026
First PostedSep 20, 2021
Enrollment StartOct 7, 2021
Primary CompletionDec 10, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.8 years ago
Interventions
PF-07304814drug
PF-07304814 is an anti-viral, formulated for intravenous delivery